Which has preferable valuation & earnings, TLX or ANNX?

Telix Pharmaceuticals has higher revenue and earnings than Annexon. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 4.18 -$7.12M N/A N/A Annexon N/A N/A -$206.69M -$1.22 N/A

Is TLX or ANNX more profitable?

Telix Pharmaceuticals' return on equity of 0.00% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Telix Pharmaceuticals N/A N/A N/A Annexon N/A -101.19% -75.99%

Does the media prefer TLX or ANNX?

In the previous week, Telix Pharmaceuticals had 3 more articles in the media than Annexon. MarketBeat recorded 8 mentions for Telix Pharmaceuticals and 5 mentions for Annexon. Annexon's average media sentiment score of 1.21 beat Telix Pharmaceuticals' score of 0.45 indicating that Annexon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Annexon 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NAMS or ANNX?

In the previous week, NewAmsterdam Pharma had 5 more articles in the media than Annexon. MarketBeat recorded 10 mentions for NewAmsterdam Pharma and 5 mentions for Annexon. Annexon's average media sentiment score of 1.21 beat NewAmsterdam Pharma's score of 0.61 indicating that Annexon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Annexon 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, ELVN or ANNX?

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enliven Therapeutics N/A N/A -$103.69M -$1.67 N/A Annexon N/A N/A -$206.69M -$1.22 N/A

Is ELVN or ANNX more profitable?

Enliven Therapeutics' return on equity of -21.04% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Enliven Therapeutics N/A -21.04% -20.41% Annexon N/A -101.19% -75.99%

Does the media refer more to ELVN or ANNX?

In the previous week, Enliven Therapeutics had 6 more articles in the media than Annexon. MarketBeat recorded 11 mentions for Enliven Therapeutics and 5 mentions for Annexon. Annexon's average media sentiment score of 1.21 beat Enliven Therapeutics' score of 1.18 indicating that Annexon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Annexon 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IDYA or ANNX more profitable?

IDEAYA Biosciences' return on equity of -14.24% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets IDEAYA Biosciences N/A -14.24% -13.09% Annexon N/A -101.19% -75.99%

Does the media favor IDYA or ANNX?

In the previous week, IDEAYA Biosciences had 5 more articles in the media than Annexon. MarketBeat recorded 10 mentions for IDEAYA Biosciences and 5 mentions for Annexon. Annexon's average media sentiment score of 1.21 beat IDEAYA Biosciences' score of 0.73 indicating that Annexon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Annexon 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ANNX or GMTX?

Annexon currently has a consensus price target of $15.33, suggesting a potential upside of 201.24%. Given Annexon's stronger consensus rating and higher probable upside, analysts clearly believe Annexon is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Annexon 3 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.20 Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, ANNX or GMTX?

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Annexon N/A N/A -$206.69M -$1.22 N/A Gemini Therapeutics N/A N/A -$71.87M -$1.00 N/A

Is ANNX or GMTX more profitable?

Gemini Therapeutics' return on equity of -38.78% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Annexon N/A -101.19% -75.99% Gemini Therapeutics N/A -38.78% -35.88%

Annexon (ANNX) Competitors

$5.09 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$5.10 +0.00 (+0.10%)

As of 07/31/2026 07:34 PM Eastern

Compare

ANNX vs. TLX, NAMS, ELVN, IDYA, and GMTX

Should you buy Annexon stock or one of its competitors? MarketBeat compares Annexon with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Annexon include Telix Pharmaceuticals (TLX), NewAmsterdam Pharma (NAMS), Enliven Therapeutics (ELVN), IDEAYA Biosciences (IDYA), and Gemini Therapeutics (GMTX).

How does Annexon compare to Telix Pharmaceuticals?

Telix Pharmaceuticals (NASDAQ:TLX) and Annexon (NASDAQ:ANNX) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

Telix Pharmaceuticals presently has a consensus target price of $20.40, suggesting a potential upside of 106.27%. Annexon has a consensus target price of $15.33, suggesting a potential upside of 201.24%. Given Annexon's higher probable upside, analysts plainly believe Annexon is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63
Annexon	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.20

Telix Pharmaceuticals' return on equity of 0.00% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Annexon	N/A	-101.19%	-75.99%

Telix Pharmaceuticals has higher revenue and earnings than Annexon.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	4.18	-$7.12M	N/A	N/A
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A

In the previous week, Telix Pharmaceuticals had 3 more articles in the media than Annexon. MarketBeat recorded 8 mentions for Telix Pharmaceuticals and 5 mentions for Annexon. Annexon's average media sentiment score of 1.21 beat Telix Pharmaceuticals' score of 0.45 indicating that Annexon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Annexon	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Telix Pharmaceuticals has a beta of -0.24, meaning that its share price is 124% less volatile than the broader market. Comparatively, Annexon has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market.

Summary

Telix Pharmaceuticals beats Annexon on 7 of the 11 factors compared between the two stocks.

How does Annexon compare to NewAmsterdam Pharma?

NewAmsterdam Pharma (NASDAQ:NAMS) and Annexon (NASDAQ:ANNX) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership.

Annexon has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -943.23%. NewAmsterdam Pharma's return on equity of -26.49% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%
Annexon	N/A	-101.19%	-75.99%

In the previous week, NewAmsterdam Pharma had 5 more articles in the media than Annexon. MarketBeat recorded 10 mentions for NewAmsterdam Pharma and 5 mentions for Annexon. Annexon's average media sentiment score of 1.21 beat NewAmsterdam Pharma's score of 0.61 indicating that Annexon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Annexon	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NewAmsterdam Pharma presently has a consensus price target of $49.42, indicating a potential upside of 77.82%. Annexon has a consensus price target of $15.33, indicating a potential upside of 201.24%. Given Annexon's higher probable upside, analysts plainly believe Annexon is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93
Annexon	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.20

NewAmsterdam Pharma has a beta of 0.1, indicating that its share price is 90% less volatile than the broader market. Comparatively, Annexon has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market.

NewAmsterdam Pharma has higher revenue and earnings than Annexon. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$22.50M	144.38	-$203.82M	-$1.79	N/A
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A

89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 12.7% of NewAmsterdam Pharma shares are owned by company insiders. Comparatively, 10.3% of Annexon shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

NewAmsterdam Pharma beats Annexon on 10 of the 16 factors compared between the two stocks.

How does Annexon compare to Enliven Therapeutics?

Enliven Therapeutics (NASDAQ:ELVN) and Annexon (NASDAQ:ANNX) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

Enliven Therapeutics' return on equity of -21.04% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-21.04%	-20.41%
Annexon	N/A	-101.19%	-75.99%

Enliven Therapeutics currently has a consensus price target of $70.50, suggesting a potential upside of 28.63%. Annexon has a consensus price target of $15.33, suggesting a potential upside of 201.24%. Given Annexon's higher probable upside, analysts clearly believe Annexon is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Annexon	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Enliven Therapeutics had 6 more articles in the media than Annexon. MarketBeat recorded 11 mentions for Enliven Therapeutics and 5 mentions for Annexon. Annexon's average media sentiment score of 1.21 beat Enliven Therapeutics' score of 1.18 indicating that Annexon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Annexon	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Enliven Therapeutics has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, Annexon has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market.

95.1% of Enliven Therapeutics shares are owned by institutional investors. 3.0% of Enliven Therapeutics shares are owned by company insiders. Comparatively, 10.3% of Annexon shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A

Summary

Enliven Therapeutics beats Annexon on 7 of the 13 factors compared between the two stocks.

How does Annexon compare to IDEAYA Biosciences?

IDEAYA Biosciences (NASDAQ:IDYA) and Annexon (NASDAQ:ANNX) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

98.3% of IDEAYA Biosciences shares are owned by institutional investors. 4.7% of IDEAYA Biosciences shares are owned by company insiders. Comparatively, 10.3% of Annexon shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

IDEAYA Biosciences' return on equity of -14.24% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	N/A	-14.24%	-13.09%
Annexon	N/A	-101.19%	-75.99%

IDEAYA Biosciences presently has a consensus price target of $50.25, indicating a potential upside of 41.55%. Annexon has a consensus price target of $15.33, indicating a potential upside of 201.24%. Given Annexon's higher probable upside, analysts plainly believe Annexon is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81
Annexon	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.20

IDEAYA Biosciences has a beta of -0.09, meaning that its stock price is 109% less volatile than the broader market. Comparatively, Annexon has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market.

IDEAYA Biosciences has higher revenue and earnings than Annexon. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$225.27M	13.85	-$113.70M	-$1.60	N/A
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A

In the previous week, IDEAYA Biosciences had 5 more articles in the media than Annexon. MarketBeat recorded 10 mentions for IDEAYA Biosciences and 5 mentions for Annexon. Annexon's average media sentiment score of 1.21 beat IDEAYA Biosciences' score of 0.73 indicating that Annexon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Annexon	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

IDEAYA Biosciences beats Annexon on 8 of the 14 factors compared between the two stocks.

How does Annexon compare to Gemini Therapeutics?

Annexon (NASDAQ:ANNX) and Gemini Therapeutics (NASDAQ:GMTX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, media sentiment, analyst recommendations and dividends.

In the previous week, Annexon had 5 more articles in the media than Gemini Therapeutics. MarketBeat recorded 5 mentions for Annexon and 0 mentions for Gemini Therapeutics. Annexon's average media sentiment score of 1.21 beat Gemini Therapeutics' score of 0.00 indicating that Annexon is being referred to more favorably in the media.

Company	Overall Sentiment
Annexon	Positive
Gemini Therapeutics	Neutral

Annexon has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, suggesting that its stock price is 112% less volatile than the broader market.

75.4% of Gemini Therapeutics shares are owned by institutional investors. 10.3% of Annexon shares are owned by company insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

Annexon currently has a consensus price target of $15.33, suggesting a potential upside of 201.24%. Given Annexon's stronger consensus rating and higher probable upside, analysts clearly believe Annexon is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.20
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Gemini Therapeutics' return on equity of -38.78% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-101.19%	-75.99%
Gemini Therapeutics	N/A	-38.78%	-35.88%

Summary

Annexon beats Gemini Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Annexon News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANNX vs. The Competition

Export

Metric	Annexon	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$834.78M	$3.54B	$6.85B	$12.42B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-4.17	7.38	282.30	24.66
Price / Sales	N/A	1,203.55	564.25	75.48
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	3.58	16.95	10.98	6.07
Net Income	-$206.69M	-$12.56M	$3.49B	$347.99M
7 Day Performance	-0.78%	-1.81%	-0.60%	-0.44%
1 Month Performance	-6.78%	-8.43%	-5.19%	-4.81%
1 Year Performance	107.76%	48.41%	62.02%	18.61%

Annexon Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANNX Annexon	3.9812 of 5 stars	$5.09 flat	$15.33 +201.2%	+107.8%	$834.78M	N/A	N/A	60	Positive News Gap Up
TLX Telix Pharmaceuticals	4.1118 of 5 stars	$10.06 -0.4%	$20.40 +102.8%	-24.2%	$3.42B	$803.79M	N/A	1,184
NAMS NewAmsterdam Pharma	2.5763 of 5 stars	$28.46 +2.0%	$49.42 +73.6%	+30.6%	$3.33B	$22.50M	N/A	4	Upcoming Earnings Gap Up
ELVN Enliven Therapeutics	3.0604 of 5 stars	$53.95 +1.9%	$70.50 +30.7%	+192.6%	$3.29B	N/A	N/A	50	Positive News
IDYA IDEAYA Biosciences	3.743 of 5 stars	$36.45 +2.4%	$50.25 +37.8%	+46.3%	$3.20B	$218.71M	N/A	80	News Coverage Upcoming Earnings Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANNX) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Annexon (ANNX) Competitors

ANNX vs. TLX, NAMS, ELVN, IDYA, and GMTX

How does Annexon compare to Telix Pharmaceuticals?

Summary

How does Annexon compare to NewAmsterdam Pharma?

Summary

How does Annexon compare to Enliven Therapeutics?

Summary

How does Annexon compare to IDEAYA Biosciences?

Summary

How does Annexon compare to Gemini Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANNX vs. The Competition

Annexon Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Annexon (ANNX) Competitors

ANNX vs. TLX, NAMS, ELVN, IDYA, and GMTX

How does Annexon compare to Telix Pharmaceuticals?

Do analysts rate TLX or ANNX?

Is TLX or ANNX more profitable?

Which has preferable valuation & earnings, TLX or ANNX?

Does the media prefer TLX or ANNX?

Which has more volatility & risk, TLX or ANNX?

Summary

How does Annexon compare to NewAmsterdam Pharma?

Is NAMS or ANNX more profitable?

Does the media favor NAMS or ANNX?

Do analysts rate NAMS or ANNX?

Which has more risk and volatility, NAMS or ANNX?

Which has stronger valuation & earnings, NAMS or ANNX?

Do institutionals & insiders believe in NAMS or ANNX?

Summary

How does Annexon compare to Enliven Therapeutics?

Is ELVN or ANNX more profitable?

Do analysts prefer ELVN or ANNX?

Does the media refer more to ELVN or ANNX?

Which has more risk and volatility, ELVN or ANNX?

Do institutionals and insiders hold more shares of ELVN or ANNX?

Which has higher valuation and earnings, ELVN or ANNX?

Summary

How does Annexon compare to IDEAYA Biosciences?

Do insiders and institutionals believe in IDYA or ANNX?

Is IDYA or ANNX more profitable?

Do analysts prefer IDYA or ANNX?

Which has more volatility & risk, IDYA or ANNX?

Which has stronger valuation and earnings, IDYA or ANNX?

Does the media favor IDYA or ANNX?

Summary

How does Annexon compare to Gemini Therapeutics?

Does the media refer more to ANNX or GMTX?

Which has more volatility & risk, ANNX or GMTX?

Do insiders & institutionals hold more shares of ANNX or GMTX?

Which has higher valuation & earnings, ANNX or GMTX?

Do analysts recommend ANNX or GMTX?

Is ANNX or GMTX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANNX vs. The Competition

Annexon Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools